期刊
CIRCULATION JOURNAL
卷 74, 期 4, 页码 760-770出版社
JAPANESE CIRCULATION SOC
DOI: 10.1253/circj.CJ-09-0580
关键词
Angiotensin-converting enzyme inhibitor; Histone deacetylase inhibitor; Monocrotaline; Pulmonary artery banding; Right ventricular hypertrophy
资金
- Ministry for Health, Welfare & Family Affairs, Republic of Korea [A083869]
- Chonnam National University Hospital Research Institute of Clinical Medicine [CRI09059-1]
- Medical Research Center for Gene Regulation at Chonnam National University [R13-2002-013-05001]
Background: Although right ventricular hypertrophy (RVH) is an adaptive process to stresses such as outflow tract obstruction, uncorrected persistent RVH often results in failure of the right ventricle or even the left ventricle. Histone deacetylase (HDAC) inhibitors can effectively prevent or block left ventricular hypertrophy, so the present study compared the effects of sodium valproate, an HDAC inhibitor, with those of captopril, an angiotensin-converting enzyme inhibitor, on RVH. Methods and Results: RVH was induced in rats by pulmonary artery banding (PAB) or monocrotaline (MCT) injection, and then either sodium valproate or captopril was administered. PAB or MCT injection caused a marked increase in the size of RV after 2 weeks, which was documented by weighing it, by evaluating echocardiograms or electrocardiograms, or by examining cardiac hypertrophy-associated gene expression. Sodium valproate significantly reduced RVH induced by either PAB or MCT injection. Interestingly, however, captopril failed to do so. Conclusions: In the present study sodium valproate, but not captopril, was effective in blocking RVH induced by PAB or MCT injection, which suggests that HDAC inhibitors may be a novel therapy for RVH. (Circ J 2010; 74: 760-770)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据